Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

This Harvard Medical School Continuing Education video examines these key questions: What are the cardiovascular and kidney benefits of SGLT2 inhibitors (SGLTi) and GLP-1 receptor agonists (GLP1 RA)? When would you choose SGLT2i versus GLP-1 RA?
Dr. Lee-Ching Chang, MD, an endocrinologist at Brigham and Women’s Hospital, reviews key trials highlighting the benefits of SGLT2i and GLP-1 RAs and the compelling reasons for choosing one over the other. Medical indications, comorbidities and side effects, and administration differences are discussed.
00:00 | Introduction
01:00 | Cardiovascular outcomes trials
04:51 | Kidney outcomes trials
06:21 | Choosing SGLT1 inhibitors vs GLP-1 receptor agonists
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.
References:
Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes. J Am Coll Cardio. 2020: 76(9): 1117-45. Published 2020 Sep 1. Accessed 22 Jan 2022.
Notice: At this time, the content in this video is not accredited.